Member Info for Seawitch65

The Zak Mir Sunday Technical Update.

​Zak Mir released his "Week in Small Caps" report today, Sunday, February 8, 2026. It sets the narrative for retail traders to look at HEMO tomorrow morning.

​1. The "1,325p" Beacon

​Mir has officially shifted his target. He previously looked at 931p, but today he stated that while the stock remains above 1,000p, the next clear technical target is £13.25 (1,325p).

​2. The "No News" Momentum

​Mir noted that HEMO moved nearly 50% in a week (from the 774p lows) on "no news."

​A 50% move on no news is almost always seen as Smart Money positioning ahead of an RNS.

Yep.If they’ve truly reduced that burn rate as you suggest, i agree that £2m could see them through to June.

If that's the case then they don't need a massive £20m ( whatever) raise . They just need a small bridge like a CLN to get them to the Patient 4 results or the buyout announcement.

Great post.The real tell isn't Vlad's salary—it’s how they bridge that £5.6m shortfall this month. If it's needed and If we see an RNS for a CLN instead of a standard placing, it’s a massive signal. It suggests the board is protecting the equity for a buyout rather than diluting us at these levels.

What do we think? 2 x Rns next week?

Colorado news first.Itumbula second?

A classic one-two punch.😁

Good news takes the Sp firstly to @ .50?

And then up to .65? Am i being too conservative?

Pure speculation of course.

Yes.HOPHF is a ghost town most days!. I was actually looking at the Market Maker 'Ask' quotes at the US close.i.e not volume,but pricing pressure. Even with no trades, they moved the offer up to track the London spike. But you're right, the LSE is the only place with real liquidity. 1,100p is the number that matters for Monday.Final trade yesterday executed at 1,132.😁

Finally from me...

Institutional Handover: The final trades in both London and the US were "Buy Imbalanced." This means larger funds were absorbing any retail selling, usually a precursor to a major news announcement.

​Safety Check: There were zero large-scale "Sell" blocks detected in the US after-hours, which would have been a red flag for a "placing" (discounted cash raise) .gemini alert.

The US price settled at a slight premium to the UK close, suggesting that US traders are expecting a "Gap Up"when London opens on Monday.

​Volume: Trading was light but consistent. Importantly, there was no late-session sell-off in the US, which indicates that "weak hands" aren't panicking ahead of the weekend.

​Sentiment: American message boards are heavily focused on the Patient 4 update and the Eli Lilly connection, viewing the London price action as "insider" positioning.

​Momentum: The US performance "protects" the 1,132p floor, making a pullback on Monday morning less likely unless bad news drops at 7:00 AM.( gemini)

Let's see what happens after the lunchtime lull....

Wow! This sort of increase on no news makes me nervous! Of course there will be a dip before day end as the day traders exit.

Talk about a "pre-emptive strike" by the market.

​ People are betting the Feb 24th anniversary news is going to be so good that they are buying in at any price to avoid being left behind.Could there be a " leak" over the w/ end?

​Either that or a Short Squeeze.

I put a small Sell order in at 12.. & im not far off now!.this is crazy!!

Even if we dont break 1000 tomorrow,if we can maintain high 900s it bodes well for a good start on Monday.

Those warrants raised £190,000 .

​

Certainly hoping for 18 but🤞you are right.

Id suggest that the next RNS might align with patient no.1 12 month survival( around the 24/2).Thats about 3 months since the last RNS which is a usual timeline for RNS release from HEMO?

Larger institutional investors coming on board?if that' s the case,we're getting close

Clearly the market agrees with you.

At todays 800 this share price has risen approx 48% in the last 4 weeks on no news.

A very significant move for a four-week period, outperforming most market benchmarks and reflecting strong bullish momentum for Us.

GOOD morning All...Im actually green for once.Wonder how long that will last!

The Hematology Giants: Novartis & Sanofi

​Novartis: As the pioneer of the first-ever CAR-T (Kymriah), Novartis is always looking for next-generation platforms. Hemogenyx’s Chimeric Bait Receptor (CBR) platform, which targets both viral infections and cancer, fits Novartis's "broad-platform" investment strategy.

​Sanofi: Sanofi has been aggressively pivoting toward immunology and oncology. In early 2026, they are in an active "portfolio management" phase, seeking to add new Phase 1/2 programs to their pipeline to replace aging blockbusters.

​ Speculative "Deep Pocket" Candidates

​AstraZeneca: They have been rapidly expanding their presence in cell therapy and recently acquired companies like Gracell Biotechnologies. Hemogenyx would be a relatively low-cost acquisition with high upside if the AML data is positive.

​Johnson & Johnson (Janssen): After their success with Carvykti, J&J is looking for ways to expand cell therapy into more common and deadly blood cancers.( gemini)

The CAR-T Leaders: Bristol Myers Squibb (BMS) & Gilead

​These two companies are the current "industrialists" of the CAR-T world, with products like Abecma, Breyanzi (BMS), and Yescarta (Gilead/Kite).

​BMS: They have shown a continuous appetite for early-stage cell therapy assets that can treat "harder" targets like AML.

​Gilead (Kite Pharma): Gilead frequently acquires smaller biotechs to maintain its dominance in the cell therapy space. Hemogenyx’s focus on FLT3+ AML would be a natural extension of their hematology portfolio.( gemini)

Lilly has an exclusive worldwide license for the CDX antibody. If clinical data from Phase I is strong, Lilly may choose to buy the company outright to consolidate the asset and the underlying technology platform rather than just paying royalties.

Green Flag (The "Gap Up"): If the price holds above 800p for more than three days, it suggests institutional investors (the big money) are starting to build positions, not just day traders.

​Red Flag (The "Placebo Rally"): If there is no official news (RNS) within the next 48 hours, today’s jump might be a "short squeeze" or a rumor. Be careful of a "pullback" to the 700p level.